What is propranolol studying for multiple myeloma?

Propranolol is being studied to see how adding it to standard treatment affects immune response and quality of life in patients with newly diagnosed multiple myeloma. Researchers aim to understand whether this beta-blocker can influence health outcomes alongside other lifestyle interventions. This study is sponsored by Roswell Park Cancer Institute.

Who may be eligible for this multiple myeloma clinical trial?

Adults aged 18 and older diagnosed with multiple myeloma, smoldering multiple myeloma, plasma cell leukemia, or low-risk myelodysplastic syndrome may be eligible. Both males and females can participate, with some requirements for females of child-bearing potential. Participants should be able to follow the study procedures and have no major health issues that would pose risks. Please review eligibility criteria for more details.

Is there any cost to participate in this multiple myeloma clinical trial?

Study-related care, including the study drug or procedure and all trial visits, is provided at no cost. However, personal travel expenses may vary and are not guaranteed to be covered. Participants should plan accordingly for any travel or related costs.

Actively Recruiting

Phase Not Applicable

Age: 18Years +

All Genders

ID05312255

Study of Non-Chemotherapy Approaches Including Physical Activity, Nutrition, and Beta-Blocker Treatment to Improve Immune Health and Quality of Life in Patients with Multiple Myeloma or Related Blood Disorders

Led by Roswell Park Cancer Institute · Updated on 2025-12-01

175

Participants Needed

Research Sites

N/A

Total Duration

AI-Summary

What this Trial Is About

Researchers are evaluating how non-chemotherapy interventions affect patients with multiple myeloma or myelodysplastic syndrome MDS. This study explores the impact of physical activity, nutritional changes, and the addition of the beta-blocker propranolol to standard treatment on immune function and quality of life. Previous observations suggest beta-blockers might improve survival for multiple myeloma patients during chemotherapy, so this study aims to further understand these effects in newly diagnosed patients. Participants are assigned to different modules based on their condition and treatment status. Module A involves twice-weekly strength training via internet supervision and wearing a FitBit for 6 months. Module B includes intermittent fasting with an 8-hour eating window daily for 1 month. Module C compares two groups one receives propranolol twice daily for 3 months, and the other continues their standard beta-blocker regimen for 3 months. Module D, for patients with low-risk MDS, offers resistance training twice weekly for 6 months. Follow-up visits occur after the interventions, varying from 3 months to 1 year depending on the module. During the study, participants undergo assessments of immune cells, bone markers, body composition, stress levels, anxiety, fatigue, and physical function at multiple time points. Researchers also analyze changes in the gut microbiome and nutritional behaviors. Data is collected through devices, questionnaires, and laboratory tests. The primary outcome is immune cell changes measured at baseline and after one year. Participants health and safety are monitored throughout, with study durations ranging from 1 to 6 months for interventions plus follow-up periods.

CONDITIONS

Brief Title

Non-chemotherapeutic Interventions for the Improvement of Quality of Life and Immune Function in Patients With Multiple Myeloma

How This Trial Compares With Other Options

This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.

Factors	Strength training plus Fitbit prompts	Intermittent fasting	Propranolol (new dosing)	Standard beta‑blocker regimen	Strength training for low‑risk MDS
What this is	Resistance training for 6 months combined with Fitbit‑prompt behavioral support	A period of intermittent fasting (limited‑time daily eating window)	New propranolol dosing regimen for about 3 months before systemic therapy	Continuation of standard beta‑blocker regimen over same duration	Strength training combined with device prompts for low‑risk MDS patients
Role in trial	Experimental intervention tested in trial protocol	Experimental intervention tested in trial protocol	Investigational propranolol dose tested against standard regimen	Comparator arm with current beta‑blocker practice	Experimental intervention applying physical activity in MDS context
Primary use	To improve immune function and quality of life through physical activity	To assess effects of dietary timing on immune and quality of life outcomes	To evaluate propranolol’s influence on immune response and quality of life	To serve as standard‑dose comparator in immune and quality of life assessment	To improve immune function and quality of life through strength training in MDS
How it is given or performed	Participants perform resistance training and receive Fitbit activity prompts for six months	Participants follow an intermittent fasting schedule with limited daily eating window	Oral propranolol dosing before systemic therapy over about three months	Continue standard oral beta‑blocker regimen over same period	Participants engage in strength training and Fitbit‑based prompts in low‑risk MDS over six months
External evidence on similar approaches	Exercise may be safe and feasible in MM, with mixed impact on fatigue and quality of life	Intermittent fasting and exercise may improve quality of life and biomarkers, though evidence remains limited	Beta‑blocker use, including propranolol, has been associated with improved survival in observational MM studies; preclinical data show anti‑myeloma effects	Continuing standard beta‑blocker therapy aligns with usual cardiovascular management; its impact on MM outcomes is observational	Strength training may improve quality of life in hematologic disorders, but MM‑specific evidence is sparse
Important risks	Potential for bone instability or fractures during resistance training—exclusion criteria reflect this risk	Risk of malnutrition or unsuitability of fasting in certain metabolic conditions	Standard contraindications to beta‑blockers apply (e.g., bradycardia, severe asthma, uncontrolled heart conditions)	Same as investigational arm—contraindications apply	Physical risks similar to Module A if musculoskeletal instability is present
Important limitations	Effects may vary by bone involvement; evidence of benefit on fatigue and QoL in MM is mixed	Evidence is limited and heterogenous; fasting safety and efficacy in MM not well established	Association with survival is observational; no randomized data in MM existing yet	Not designed to examine treatment efficacy in MM—serves as cardiovascular care comparison	Applicability to MM uncertain; data in MDS may not generalize

Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.

Who Can Participate

Age: 18Years +

All Genders

Eligibility Criteria

You may qualify if you...

Age 18 years or older
Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1 for Modules A and D, 0-2 for Modules B and C
Diagnosis of smoldering multiple myeloma, multiple myeloma, or plasma cell leukemia for Modules A, B, and C
Diagnosis of non-transfusion-dependent low-risk myelodysplastic syndrome for Module D
No comorbidities, myeloma symptoms, or treatment side effects that pose danger as determined by physician
Ability to understand and follow assessment and intervention procedures
Signed informed consent
Access to a personal computer or tablet with camera, microphone, speakers, and internet for Modules A and D
Newly diagnosed multiple myeloma patients requiring treatment before systemic therapy initiation for Module C
Female participants of child-bearing potential must have negative pregnancy test and agree to use adequate contraception; male participants with female partners of child-bearing potential must use contraception

You will not qualify if you...

Major comorbidities posing danger during study, including cardiac, pulmonary, infectious diseases, psychiatric illness, or social situations limiting study compliance
Unwillingness or inability to follow protocol requirements
Investigator-determined unsuitability due to comorbidities, myeloma symptoms, or treatment side effects
For Module A: current symptomatic pathological fractures or severe musculoskeletal instability
For Module A: acute bone instability as assessed by imaging and surgeon evaluation
For Module B: clinical signs of malnutrition (BMI below 18), special physician-prescribed diets, diabetes treated with glucose-lowering medications or insulin, or conditions unsuitable for food restriction
For Module C: current or recent beta-blocker use within 3 months
For Module C: contraindications to beta-blockers including severe bradycardia, heart block, uncontrolled depression, unstable angina, uncontrolled heart failure (NYHA III or IV), hypotension, severe asthma or COPD, uncontrolled diabetes, symptomatic peripheral arterial disease or Raynaud's syndrome, untreated pheochromocytoma, current use of certain calcium channel blockers or rhythm control agents, and presence of pacemaker
For Module C: pregnancy or nursing females
For Module D: cardiovascular disease limiting exercise readiness as judged by cardiologist

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Treatment

Duration - 1 to 6 months depending on assigned module

Participants undergo assigned interventions including strength training, intermittent fasting, or beta-blocker medication depending on their module assignment.

Twice weekly sessions for 6 months for strength training; 1 month of intermittent fasting; daily propranolol for 3 months

Follow-up

Duration - Up to 1 year depending on module

Participants are followed after completion of their assigned intervention to assess long-term effects on immune function, quality of life, and other health measures.

Every 3 months for 1 year for Module A; visits at 3 and 5 months for Module B; 3 months for Module C

How is the study designed?

Study Type

INTERVENTIONAL

Masking

NONE

Allocation

NON_RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

Similar Trials

Phase I Study of VSV-hIFNbeta-NIS Vaccine Alone or With Cycl...

B-Cell Non-Hodgkin Lymphoma

Actively Recruiting

2 locations

Phase 2 Study of Maintenance Therapy Using Belantamab Mafodo...

Plasma Cell Myeloma

Actively Recruiting

1 location

Phase III Study Comparing Three-Drug Induction and Maintenan...

Plasma Cell Myeloma

Actively Recruiting

397 locations

Phase I Study of VSV-hIFNbeta-NIS Vaccine Alone or With Cyclophosphamide and Immunotherapy for Relapsed or Resistant Blood Cancers Including Multiple Myeloma, Leukemia, and Lymphoma

Phase 2 Study of Maintenance Therapy Using Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Patients With High-Risk Multiple Myeloma After Stem Cell Transplant

Phase III Study Comparing Three-Drug Induction and Maintenance Treatments for Frail or Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant

Study of Iberdomide Alone or with Dexamethasone in Adults with Intermediate- or High-Risk Smoldering Multiple Myeloma Phase 2 Clinical Trial to Evaluate Treatment Safety and Effectiveness

Safety and Effectiveness of 89ZrDFO-YS5 PET Imaging to Detect CD46 Positive Multiple Myeloma Lesions

Phase 2 Study of Leflunomide Combined with Pomalidomide and Dexamethasone for Treating Relapsed or Resistant Multiple Myeloma

Study Comparing Lenalidomide and Dexamethasone With or Without Daratumumab for High-Risk Smoldering Myeloma

Using Loratadine to Prevent Bone Pain Caused by G-CSF During Stem Cell Collection in Multiple Myeloma Patients

Study of Low-Dose Radiotherapy to Treat Painful Bone Metastases in Multiple Myeloma Patients

Study of Brain Radiation Effects on Thinking and Quality of Life in Adults with Blood Cancers

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here

Study of Non-Chemotherapy Approaches Including Physical Activity, Nutrition, and Beta-Blocker Treatment to Improve Immune Health and Quality of Life in Patients with Multiple Myeloma or Related Blood Disorders

On this page

Sponsors

AI-Summary

What this Trial Is About

Brief Title

How This Trial Compares With Other Options

Who Can Participate

Eligibility Criteria

Your Study Journey

How is the study designed?

Similar Trials

Phase I Study of VSV-hIFNbeta-NIS Vaccine Alone or With Cycl...

Phase 2 Study of Maintenance Therapy Using Belantamab Mafodo...

Phase III Study Comparing Three-Drug Induction and Maintenan...

Frequently Asked Questions

What is propranolol studying for multiple myeloma?

Who may be eligible for this multiple myeloma clinical trial?

Is there any cost to participate in this multiple myeloma clinical trial?

Will I receive propranolol or a placebo?

How will the study measure changes related to multiple myeloma?

What happens after this multiple myeloma clinical trial ends?

Can I leave this multiple myeloma clinical trial if I change my mind?

Not the Right Trial for You?

On this page

Sponsors

Sponsors

How This Trial Compares With Other Options

Who Can Participate

Eligibility Criteria

Your Study Journey

How is the study designed?

Similar Trials

Phase I Study of VSV-hIFNbeta-NIS Vaccine Alone or With Cycl...

Phase 2 Study of Maintenance Therapy Using Belantamab Mafodo...

Phase III Study Comparing Three-Drug Induction and Maintenan...

Frequently Asked Questions

What is propranolol studying for multiple myeloma?

Who may be eligible for this multiple myeloma clinical trial?

Is there any cost to participate in this multiple myeloma clinical trial?

Will I receive propranolol or a placebo?

How will the study measure changes related to multiple myeloma?

What happens after this multiple myeloma clinical trial ends?

Can I leave this multiple myeloma clinical trial if I change my mind?

Sponsors